Drug Trial Radar · NCT06662097
A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Oct 16, 2024
Primary completion
Jan 2, 2026
Study completion Jan 28, 2026
Sponsor
- Lead sponsor
- Alume Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery
Conditions
- Surgery
- Nerve Injury
- Imaging
Interventions
BevonesceinDrug
Bevonescein is a sterile solution that is intravenously administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fluorescence System SurveyTime frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Diego
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.